<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844623</url>
  </required_header>
  <id_info>
    <org_study_id>TK99UN-HCC1</org_study_id>
    <nct_id>NCT00844623</nct_id>
  </id_info>
  <brief_title>TK-based Suicide Gene Therapy for Hepatocellular Carcinoma</brief_title>
  <official_title>Phase I Clinical Trial Of Gene Therapy For Hepatocellular Carcinoma By Intratumoral Injection Of TK99UN (An Adenoviral Vector Containing The Thymidine Kinase Of Herpes Simplex Virus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether activation of a prodrug after intratumoral
      gene transfer is safe in humans, and to determine dose levels for further clinical
      development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a phase I clinical trial evaluating the intratumoral injection of defective
      adenovirus containing HSVtk (the thymidine kinase of herpes simplex virus), in patients with
      advanced hepatocellular carcinoma that were not amenable to curative therapy. The study was
      conducted in a single center in Spain. Five consecutive cohorts of two patients received
      increasing doses of the vector by intratumoral injection and equal doses of either
      intravenous ganciclovir or oral valganciclovir. The dose received by each consecutive cohort
      of patients was progressively higher according to a prefixed scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Daily for the first 16 day, monthly thereafter for 6 months, 3-monthly since then</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response by WHO criteria</measure>
    <time_frame>at day 63 and months 4, 6, 9 y 12</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>TK99UN</intervention_name>
    <description>escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally</description>
    <other_name>Adenoviral vector encoding for HSV-TK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unequivocal diagnosis of hepatocellular carcinoma according to histological
             confirmation or EASL-AASLD criteria

          -  Contraindication for surgical treatment of the disease

          -  Detectable disease by imaging

          -  Ability to give informed consent and to express the willingness to fulfill protocol
             requirements during the study

        Exclusion Criteria:

          -  Current pregnancy or breast-feeding

          -  Acute infection

          -  Positive anti-HIV antibodies

          -  Hematologic alterations not attributable to hypersplenism, or in any case, intense
             neutropenia and thrombocytopenia, defined as neutrophil count lower than 0,5/pL or
             platelet count lower than 20/pL

          -  Participation in other clinical trial during the previous month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus Prieto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Sangro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Peñuelas I, Mazzolini G, Boán JF, Sangro B, Martí-Climent J, Ruiz M, Ruiz J, Satyamurthy N, Qian C, Barrio JR, Phelps ME, Richter JA, Gambhir SS, Prieto J. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005 Jun;128(7):1787-95.</citation>
    <PMID>15940613</PMID>
  </reference>
  <results_reference>
    <citation>Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, Qian C, Benito A, Larrache J, Olagüe C, Boan J, Peñuelas I, Sádaba B, Prieto J. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 2010 Dec;17(12):837-43. doi: 10.1038/cgt.2010.40. Epub 2010 Aug 6.</citation>
    <PMID>20689572</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Universidad de Navarra, Universidad de Navarra</investigator_affiliation>
    <investigator_full_name>Bruno Sangro Gomez-Acebo</investigator_full_name>
    <investigator_title>Main investigator</investigator_title>
  </responsible_party>
  <keyword>primary liver cancer, hepatoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

